Abstract. Since 
elevate basal and TRH-stimulated TSH-serum levels and since this effect was also shown after iv administration of the novel dopamine antagonistic agent domperidone, it was investigated, whether this antiemetic drug could interfere after oral intake with the evaluation of thyroid function. Oral domperidone caused a marked TSH\x=req-\ enhancement of TRH-induced TSH increments in 6 out of 14 euthyroid subjects, with no statistical significance, however. The difference between oral and parenteral influence as well as inter-individual changes are probably due to the varying first pass effect of the drug after oral absorption.
It is known that the dominant inhibitory control of thyrotrophin (TSH) release is mediated by the central neurotransmitter dopamine and that antidopaminergic drugs, such as metoclopramide and sulpiride are capable of enhancing TSH-secretion in both normal and, particularly, hypothyroid sub¬ jects (Delitala 1977; Healy & Burger 1977; Scanlon et al. 1977; Massara et al. 1978; Zanoboni et al. 1979 ). Metoclopramide increases TSH-levels in serum of normal subjects after iv (Scanlon et (Wenzel 1981) . It was even proposed to use the enhancing effect on TSH-secretion of metoclopramide as a diagnostic tool for the recog¬ nition of subclinical hypothyroidism (Scanlon et al. 1979) or preclinical hyperthyroidism Staubetal. 1980 (Delitala et al. 1980) or by iv application (Pourmand et al. 1980; Scanlon et al. 1981; Massaraetal. 1981 Especially in consideration of the importance (Wenzel 1979) (Powell et al. 1981 (Meuldermans et al. 1977) , and in human volunteers only 14% of the radioactivity present in the plasma after oral intake of labelled domperidone was due to the unchanged drug while only 0.4% of the oral dose was excreted unchanged, indicating that domperidone was ex¬ tensively metabolized in the liver before reaching central circulation (Heykants et al. 1977) . More¬ over, the inter-individual amount of unchanged drug in the plasma differed by a factor up to 2.4 (Heykants et al. 1977) . These data indicate that the 'first pass effect' of domperidone is responsible for the lacking TSH increase and for the inter-indivi¬ dual differences in this study. Retrospectively, it is conspicuous that 5 out of 7 publications dealing with the effect of metoclopramide on TSH levels were done with oral administration, whereas all of the 5 existing studies with domperidone were done by parenteral application. 
